Advertisement
The company's latest report, 'Pancreatic Cancer: Opportunity Analysis and Forecast to 2029', identifies CP-613 (devimistat), developed by Rafael Pharmaceuticals and TAK-931 (simurosertib), by Takeda & Co, to be the lead candidates in the first-line setting from a clinical and commercial standpoint. Launches for NTRK inhibitors Vitrakvi® and Rozlytrek® in the 5EU and *ASPAC will provide further market growth and diversification. This forecast period will likely also see introduction of novel agents, namely CORT 125134 (relacorilant) and SM-88 (racemetyrosine) in the third-line setting, where currently no specific treatment exists and supportive care is heavily relied upon.
Advertisement
Aarohi Rede, BDS, MPH, Oncology Analyst at GlobalData, comments: "Pancreatic cancer is primarily a chemotherapy dominated market, which includes low priced generic drugs currently forming the backbone of the treatment paradigm. Growth in pancreatic cancer therapy market is driven by the introduction of drugs with novel mechanisms of action, across several lines of therapies, which are poised to meet high unmet need in the US and *5EU.
"Market growth trends are indicative of a shift in market consumption from chemotherapy to use of targeted therapies, and a shift in the treatment paradigm towards personalized medicine approaches between 2019 and 2029. Kinase inhibitors, constituting several late-stage pipeline agents, are expected to be the frontrunners over the forecast period, leading to significant market expansion."
Pancreatic cancer is marked with expression of several genetic mutations and tumor biomarkers, many of which, such as NTRK gene fusions, PD-1/PD-L1 checkpoint inhibition, elevated levels of microsatellite instability (MSI) levels, PARP inhibition are considered actionable mutations and have been utilized to target tumoral cells by recently launched targeted therapies. Although applicable in a small percentage of populations, Key Opinion Leaders (KOLs) interviewed by GlobalData have identified these drugs to be revolutionary in pancreatic cancer from a clinical standpoint. With Keytruda® and Lynparza® seeking label expansion in different lines in advanced disease settings.
Rede continues: "Pancreatic cancer has historically been an indication with high unmet need with delayed detection of the disease, rapid progression, lack of effective therapies, high clinical trial failure rates and poor survival outcomes. With these drugs gaining more popularity among treating physicians, there is a growing emphasis around biomarker testing and early detection. These agents provide a unique opportunity for patients expressing these biomarkers to obtain superior clinical results in combination with other established agents.
"Pancreatic cancer is a high-need, high-opportunity oncology indication with growing incidence globally. GlobalData has identified Urban China as a high growth market in this indication, being classified as a one of the largest pancreatic cancer markets along with the US and Japan in 2029. The US, however, is still expected to be the market leader in 2029, being valued 2.5 times as much in 2019, thus highlighting interesting market dynamics for this indication based on incidence rates, clinical approaches and product commercialization."
*8MM = US, France, Germany, Italy, Spain, the UK, Japan, and Urban China
*5EU = France, Germany, Italy, Spain, the UK
*ASPAC = Japan, Urban China
